Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. [electronic resource]
Producer: 20190624Description: 2769-2781 p. digitalISSN:- 1029-2403
- Adenine -- analogs & derivatives
- Agammaglobulinaemia Tyrosine Kinase -- antagonists & inhibitors
- Bridged Bicyclo Compounds, Heterocyclic -- pharmacology
- Clinical Trials as Topic
- Drug Resistance, Neoplasm -- genetics
- Humans
- Lymphoma, Mantle-Cell -- drug therapy
- Patient Selection
- Piperidines
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- Sulfonamides -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.